Form 4: NeoGenomics CEO Anthony Zook Reports Significant Equity Grants and Routine Share Transactions

NeoGenomics, Inc. CEO and Director Anthony P. Zook has reported the vesting of restricted stock units, related tax-driven share disposals, and substantial new equity grants, including stock options and restricted stock units.

Summary

• Anthony P. Zook, Chief Executive Officer and Director of NeoGenomics, Inc. (NEO), reported transactions on June 1, 2025.
• Mr. Zook acquired 12,254 shares of common stock through the release of previously reported restricted stock units (RSUs) at a price of $0.
• Concurrently, 3,424 shares were disposed of at $0 to NeoGenomics, Inc. to satisfy tax obligations related to the December 1, 2024 vesting of restricted stock.
• Following these transactions, Mr. Zook directly beneficially owns 20,166 shares of common stock and indirectly owns 18,900 shares through the Amended and Restated Anthony P. Zook Living Trust, totaling 39,066 shares.
• On April 1, 2025, Mr. Zook was granted 729,927 stock options with an exercise price of $10.44, which was calculated as 110% of the closing price on the grant date; these options vest ratably over three years.
• Also on April 1, 2025, Mr. Zook was granted 421,496 restricted stock units at a price of $0, which also vest ratably over three years.
• Mr. Zook holds additional stock options: 8,353 options exercisable at $14.82 expiring August 10, 2033, and 8,672 options exercisable at $13.71 expiring June 1, 2034.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant new equity grants to the CEO, which align his incentives with long-term shareholder value. The other transactions are routine vesting and tax-related disposals, which are neutral.

Positives

• The grant of 729,927 stock options and 421,496 restricted stock units on April 1, 2025, represents a significant equity award, aligning management's long-term incentives with shareholder value.
• The vesting of restricted stock units indicates the achievement of prior performance or time-based conditions.

Negatives

• The disposal of 3,424 shares was solely for tax obligations related to RSU vesting, not a discretionary sale, and thus not inherently negative for investment sentiment.

Future Outlook

The document indicates future vesting schedules for the newly granted stock options and restricted stock units, which will occur ratably over the first three anniversary dates of the April 1, 2025 grant date. Once vested, the restricted stock units convert to common stock and are not subject to expiration.

Industry Context

This Form 4 filing details routine executive compensation and equity transactions for a CEO in the diagnostics and oncology testing industry. Such filings are standard disclosures and reflect how companies incentivize and retain key leadership through equity-based compensation, aligning their interests with long-term company performance.

Stakeholder Impact

• Shareholders: The significant equity grants to the CEO align his financial interests with the company's long-term performance, potentially benefiting shareholders if the company's stock price appreciates.
• Employees: While not directly impacting all employees, executive compensation structures can influence overall company culture and compensation philosophy.

Next Steps

• The 729,927 stock options granted on April 1, 2025, will vest ratably over the first three anniversary dates of the grant date.
• The 421,496 restricted stock units granted on April 1, 2025, will vest ratably over the first three anniversary dates of the grant date.

Key Dates

Keywords

NeoGenomics, NEO, Anthony Zook, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Equity Grants, Beneficial Ownership